CureMatch
×
  • Physicians
  • BioPharma
  • Employers
  • News
  • Clinical Order
  • About Us
  • Login

CureMatch Co-Founder Shares Findings HTLV-1 BLV Viruses Can Accelerate Development of Various Cancers

CureMatch Co-Founder Shares Findings HTLV-1 BLV Viruses Can Accelerate Development of Various Cancers
Press

CureMatch’s co-founder and Chief Science Officer, Dr. Igor Tsigelny contributed to recently published cancer research concerning impact of viruses HTLV-1 and BLV on development of various cancers which could prove helpful to future CureMatch work. Findings are hopeful that it may be possible to eradicate these viruses acceleration of various cancers.

The human T-cell leukemia virus type 1 (HTLV-1) is known to cause a rare cancer of the immune system’s T-cells called adult T-cell leukemia or ATL in about 5% of those infected. Researchers hypothesize that this virus, as well as another lesser-known “cousin” called bovine leukemia virus (BLV), may also play a role in the accelerated development of breast cancer, esophageal cancer, pancreatic cancer, and glioblastoma (brain/spinal cancer) around the world.

Kimberly Mann Bruch of UCSD and the San Diego Supercomputer Center (SDSC) highlights the recent news:

In a Journal of Cancer Research and Therapypaper published last month called HTLV-1 Can Be Involved in Acceleration of Different Nonhematological Cancers, Valentina Kouznetsova, Steven Chen, and Igor Tsigelny proposed the necessity of studies related to HTLV-1 and BLV affecting other cancers. Kouznetsova is a researcher affiliated with SDSC and on staff at the Moores Cancer Center, while Tsigelny is affiliated with both SDSC, and Moores, Chen participated on the research team via the SDSC’s Research Experience for High School Students (REHS) summer internship program.

“One of our interesting findings was that HTLV-1 infected patients in southern Japan without any manifestations of ATL-developed various cancers correlated with the possible HTLV-1 proteins influencing a set of cancer pathways equivalent to cancerogenic mutations,” said Kouznetsova, the lead author of the study.

htlv-1-cancersThis Venn diagram depicts the common significant pathways in all four cancers: HTLV-1 infection, pathways in cancer, pancreatic cancer pathway, chronic myeloid leukemia pathway, and bladder cancer pathway. Image credit: Steven Chen, SDSC/REHS.

“This problem is not easy,” added Tsigelny. “To assume that HTLV-1 virus proteins affect different cancers, one of the assumptions would have to be that the virus may spread from T-cells where it usually lives, to other types of cells. It is not obvious how that happens, but a number of anecdotal evidences show that HTLV-1 affects various cancers, not only leukemia. It is possible that other mechanisms also are involved.”

Similarly, BLV is spread from infected cattle to non-infected cattle by direct contact or exposure to blood. While BLV is not believed to survive pasteurization, the virus has the potential to be transmitted from an infected cow’s raw milk to a human. Likewise, the virus may also be able to be transmitted from an infected cow’s undercooked meat to humans. While the cattle industry strives to keep infected cattle segregated from healthy cattle, several studies have found BLV in breast cancer tumors.

According to researchers at Michigan State University (MSU), as of 2018 BLV was prevalent in about 43 percent of all U.S. cattle. However, BLV has been completely eradicated in more than 20 nations, most of which are in Europe, and their efforts can be used as models for implementing several control strategies. Large Animal Clinical Sciences Professor Paul Bartlett at MSU is currently conducting several field trials in which the most infectious cattle are culled or segregated to reduce transmission.

“Other approaches involve controlling biting flies and implementing various management controls to reduce blood-borne transmission,” said Bartlett. “Most of our earlier work involved documenting the specific ways in which BLV disrupts the bovine immune system and discovering the unexpectedly large impact on milk production and dairy cow lifespan.”

While efforts to eradicate BLV in cattle are important by themselves, the research done to date by Kouznetsova, Chen, and Tsigelny have the potential to eventually mitigate multiple cancers’ acceleration caused by those infections.

Tsigelny, along with his work at UC San Diego, is the Chief Science Officer and co-founder of CureMatch, a company which provides decision support for doctors in personalized cancer medicine.

“With 4.5 million possibilities to combine around 300 FDA-approved cancer drugs, CureMatch targets multiple cancer mutations at the same time and determines the best combination treatment for each patient,” explained Tsigelny. “While this study is not related to the current tasks of CureMatch, it may become so in the future.”

SDSC Director Michael Norman is a member of the CureMatch Advisory Board. No grant funding was used for this study.

Source: San Diego Supercomputer Center – SDSC

 

About the San Diego Super Computer Center
As an Organized Research Unit of UC San Diego, SDSC is considered a leader in data-intensive computing and cyberinfrastructure, providing resources, services, and expertise to the national research community, including industry and academia. Cyberinfrastructure refers to an accessible, integrated network of computer-based resources and expertise, focused on accelerating scientific inquiry and discovery. SDSC supports hundreds of multidisciplinary programs spanning a wide variety of domains, from earth sciences and biology to astrophysics, bioinformatics, and health IT. SDSC’s petascale Comet supercomputer is a key resource within the National Science Foundation’s XSEDE (eXtreme Science and Engineering Discovery Environment) program.

About the Journal of Cancer Research and Therapy
The Journal of Cancer Research and Therapeutics is a peer-reviewed open access medical journal published by Medknow Publications on behalf of the Association of Radiation Oncology of India. The journal covers research in oncology, radiation oncology, medical imaging, radiation protection, non-ionising radiation, and radiobiology.

About CureMatch
CureMatch, Inc. is a San Diego-based digital health company focused on personalized medicine and combination therapy in oncology. CureMatch’s Decision Support System guides oncologists in the selection of cancer drugs that are customized for individual patients based on their molecular tumor profile. CureMatch enables oncologists to become experts in personalized medicine by providing them with actionable intelligence towards advanced cancer treatment options. www.curematch.com

Share

  • LinkedIn
  • Facebook
  • Twitter
  • Reddit
  • Email
  • Print

Receive CureMatch News

Sign up for personalized oncology information and resources.
* = required field

Recent News & Resources

  • Launch of CureMatch Certified Precision Oncology Recognition Award

    CureMatch, a leader in precision oncology, is proud to announce the establishment of the CureMatch...

  • CureMatch Announces Collaboration with Mark Cuban Cost Plus Drug Company to Promote Affordable Cancer Treatment

    CureMatch, Inc., a healthcare technology company using precision medicine support for oncology, is proud to...

  • CureMatch Joins CancerX to Help Advance Innovative Cancer Treatments

    CureMatch, Inc., a healthcare technology company leveraging Knowledge Representation & Reasoning (KRR) AI for precision...

  • The Complex Cancer Puzzle | Video 1

    ShareLinkedInFacebookTwitterRedditEmailPrint

  • CureMatch and Mprobe Partner to Help Cancer Patients Determine Optimal Treatments

    CureMatch will leverage mProbe’s targeted proteomics platform to assess individual proteins within patients’ tumor tissues....

  • CureMatch Granted CPT® Code by American Medical Association for its Algorithmic Cancer Therapy Ranking Service

    Oncologists will be able to submit claims to payers using a Category III CPT code,...

  • CureMatch CEO Navid Alipour named a Top 50 Honoree Leader of Influence in Life Science by San Diego Business Journal

    Congratulations to CureMatch CEO Navid Alipour for being named a Top Leader of Influence in...

Validation

  • Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study

    Malignancies are molecularly complex and become more resistant with each line of...

  • Significance of Scores Generated by a Cancer Therapy Matching Engine for Patient Outcomes

    Oncologists need effective precision medicine tools to navigate the myriad of therapeutic...

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for...

  • The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments

    Oncology is currently the largest area of clinical health expenditures for prescription...

Archives

  • May 2024 (1)
  • October 2023 (1)
  • June 2023 (1)
  • May 2023 (1)
  • March 2023 (1)
  • January 2023 (1)
  • July 2022 (2)
  • June 2022 (2)
  • April 2022 (1)
  • March 2022 (1)
  • February 2022 (3)
  • November 2021 (1)
  • October 2021 (2)
  • August 2021 (2)
  • July 2021 (1)
  • June 2021 (4)
  • May 2021 (1)
  • April 2021 (2)
  • March 2021 (1)
  • December 2020 (2)
  • October 2020 (3)
  • April 2020 (1)
  • November 2019 (2)
  • September 2019 (1)
  • August 2019 (1)
  • July 2019 (2)
  • April 2019 (1)
  • March 2019 (2)
  • September 2018 (1)
  • August 2018 (1)
  • July 2018 (1)
  • June 2018 (5)
  • May 2018 (1)
  • April 2018 (4)
  • March 2018 (1)
  • February 2018 (3)
  • January 2018 (4)
  • December 2017 (3)
  • November 2017 (1)
  • October 2017 (1)
  • September 2017 (3)
  • August 2017 (4)
  • June 2017 (6)
  • May 2017 (9)
  • April 2017 (11)
  • March 2017 (8)
  • February 2017 (3)
  • January 2017 (5)
  • October 2016 (1)
  • September 2016 (5)
  • August 2016 (2)
  • May 2016 (1)
  • April 2016 (1)

logo

+1 (858) 215-1313

Quick Links

  • Home
  • Physicians
  • About CureMatch
  • News and Latest Posts
  • Contact Us
  • FAQ

Latest News and Results

  • Launch of CureMatch Certified Precision Oncology Recognition Award May 8

    CureMatch, a leader in precision oncology, is proud to announce the establishment of the CureMatch...

  • CureMatch Announces Collaboration with Mark Cuban Cost Plus Drug Company to Promote Affordable Cancer Treatment Oct 7

    CureMatch, Inc., a healthcare technology company using precision medicine support for oncology, is proud to...

  • CureMatch Joins CancerX to Help Advance Innovative Cancer Treatments Jun 28

    CureMatch, Inc., a healthcare technology company leveraging Knowledge Representation & Reasoning (KRR) AI for precision...

© 2025 CureMatch, Inc. CureMatch is a registered trademark.
Terms of Use | Privacy Policy | HIPAA Notice

Please fill out the information below and a CureMatch representative will reach out to you.

 

Physician Request

  • This field is for validation purposes and should be left unchanged.

 

We value and respect your privacy and will not publish, share, or sell your contact information.

View Privacy Policy

Some pages of this website are intended for healthcare professionals

This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.

Otherwise, you will be redirected to the institutional part of this website.

Thank you for your understanding.

I am a healthcare professionalI am not a healthcare professional

Get ready to utilize the latest genomics data in your practice

Rank the most promising systemic therapies for your patients

Do you need to filter out those therapies with poor outcomes

Sort through 4.5 million expertly curated combinations of drugs

Compute your own drug choices alongside CureMatch data